<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xml:lang="HR" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-142-129</article-id>
<article-id pub-id-type="doi">10.26800/LV-142-5-6-23</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group>
</article-categories>
<title-group>
<article-title>Utjecaj intrapartalne analgezije petidinom ili tramadolom na opstetri&#x010D;ke ishode &#x2013; usporedbeno dvostruko slijepo randomizirano prospektivno intervencijsko istra&#x017E;ivanje</article-title>
<trans-title-group xml:lang="en">
<trans-title>Impact of Intrapartal Analgesia Using Petihdine or Tramadol on Obstetrical Outcomes &#x2013; a Head-to-Head Randomized Double Blind Prospective Interventional Study</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1863-8198</contrib-id><name><surname>Butorac</surname><given-names>Dra&#x017E;an</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Djakovi&#x0107;</surname><given-names>Ivka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Potkonjak</surname><given-names>Ana-Meyra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuna</surname><given-names>Krunoslav</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sumpor</surname><given-names>Bla&#x017E;enka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rado&#x0161;evi&#x0107; Vrkljan</surname><given-names>Mirjana</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ko&#x0161;ec</surname><given-names>Vesna</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label>Klinika za &#x017E;enske bolesti i porodni&#x0161;tvo, Klini&#x010D;ki bolni&#x010D;ki centar Sestre milosrdnice</aff>
<aff id="aff2"><label>2</label>Odjel za ginekologiju i porodni&#x0161;tvo, Op&#x0107;a bolnica Gospi&#x0107;</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Ana-Meyra Potkonjak, dr. med. Klinika za &#x017E;enske bolesti i porodni&#x0161;tvo, Klini&#x010D;ki bolni&#x010D;ki centar Sestre milosrdnice, Vinogradska cesta 29, 10000 Zagreb; e-po&#x0161;ta: <email xlink:href="ampotkonjak@gmail.com">ampotkonjak@gmail.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>06</month><year>2020</year></pub-date>
<volume>142</volume>
<issue>5-6</issue>
<fpage>129</fpage>
<lpage>134</lpage>
<permissions>
<copyright-year>2020</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<sec><title>Cilj</title><p>Cilj istra&#x017E;ivanja bila je usporedba djelovanja tramadola i petidina tijekom poro&#x0111;aja na opstetri&#x010D;ke ishode (njihov analgetski u&#x010D;inak, trajanje poro&#x0111;aja, pojavnost nuspojava u rodilja i neonatalni status).</p></sec>
<sec><title>Metode</title><p>Djelovanje analgetika ispitano je prospektivnim usporedbenim (engl. <italic>head-to-head</italic>) randomiziranim dvostruko slijepim intervencijskim istra&#x017E;ivanjem na uzorku od 60 rodilja tijekom ro&#x010D;nog poro&#x0111;aja. U istra&#x017E;ivanju su upotrijebljene doze tramadola i petidina od 50 mg primijenjene intravenski. Pri analizi podataka slu&#x017E;ili smo se testom razlike u proporcijama dvaju nezavisnih skupova i Studentovim t-testom. Prije provedbe t-testa normalnost je ispitana Kolmogorov-Smirnovljevim testom. <italic>Rezultati:</italic> Primjena tramadola povezana je s manje prijavljenih nuspojava te kra&#x0107;im trajanjem poro&#x0111;aja u odnosu prema skupini rodilja lije&#x010D;enih petidinom. Analizom analgetskog u&#x010D;inka statisti&#x010D;ki zna&#x010D;ajno ni&#x017E;a vrijednost boli nakon 10 minuta i 30 minuta utvr&#x0111;ena je u pacijentica kojima je primijenjen petidin u odnosu prema onima na tramadolu, uz negativnu razliku osjeta boli u obje promatrane to&#x010D;ke mjerenja. Efekt primjene tramadola i&#x0161;&#x010D;eznuo je nakon 30 minuta. Nisu utvr&#x0111;ene statisti&#x010D;ki zna&#x010D;ajne razlike u karakteristikama CTG zapisa, Apgarina zbroja, vrijednosti pH iz pupkovine.</p></sec>
<sec><title>Zaklju&#x010D;ak</title><p>Prema rezultatima istra&#x017E;ivanja, tramadol skra&#x0107;uje trajanje poro&#x0111;aja, a petidin ima ja&#x010D;i analgetski u&#x010D;inak, ali i vi&#x0161;e neugodnih nuspojava za majku. Neonatalni je ishod neovisan o vrsti opioida.</p></sec>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<sec><title>Objective</title><p>The aim of the study is to compare the effects of tramadol and pethidine during labor on the obstetrical outcomes (their analgesic effect, duration of labor, and the occurrence of adverse events in mother and neonate.</p></sec>
<sec><title>Methods</title><p>The effect of analgesia was investigated by a prospective head-to-head randomized double-blind intervention study on a sample of 60 women in labor. In the study, 50 mg of tramadol and pethidine was administered intravenously. Data analysis was performed using tests of the difference of two independent proportions and Student&#x2019;s tests. Prior to the comparison of groups, normality was tested using Kolmogorov-Smirnov test. <italic>Results:</italic> The use of tramadol is associated with side effects less frequently reported and a shorter labor duration compared to the use of pethidine. Compared to tramadol, a statistically significant lower level of pain was determined after ten minutes and 30 minutes in patients among whom pethidine was used. In the tramadol group, a negative difference in the sensation of pain was determined in both points of measurement that were observed. The effect of tramadol administration vanished after 30 minutes. There were no statistically significant differences in fetal heart rate characteristics, Apgar score, and fetal acid-base status at birth.</p></sec>
<sec><title>Conclusion</title><p>According to the study, tramadol shortens the duration of labour, whereas pethidine has a stronger analgesic effect, but is also accompanied with more maternal side effects being reported. No difference in the neonatal outcome was found.</p></sec>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori OPSTETRI&#x010C;KA ANALGEZIJA &#x2013; metode</kwd><kwd>OPIOIDNI ANALGETICI &#x2013; nuspojave, terapijska uporaba</kwd><kwd>TRAMADOL &#x2013; farmakologija, nuspojave, terapijska uporaba</kwd><kwd>MEPERIDIN &#x2013; farmakologija, nuspojave, terapijska uporaba</kwd><kwd>PORO&#x0110;AJNA BOL &#x2013; farmakoterapija</kwd><kwd>KARDIOTOKOGRAFIJA</kwd><kwd>APGAR OCJENA, PROSPEKTIVNA ISTRA&#x017D;IVANJA</kwd><kwd>DVOSTRUKO SLIJEPA ISTRA&#x017D;IVANJA</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>ANALGESIA,OBSTETRICAL &#x2013; methods</kwd><kwd>ANALGESICS,OPIOID &#x2013; adverse effects, therapeutic use</kwd><kwd>TRAMADOL &#x2013; adverse effects, pharmacology, therapeutic use</kwd><kwd>MEPERIDINE &#x2013; adverse effects, pharmacology, therapeutic use</kwd><kwd>LABOR PAIN &#x2013; drug therapy</kwd><kwd>CARDIOTOCOGRAPHY</kwd><kwd>APGAR SCORE</kwd><kwd>PROSPECTIVE STUDIES</kwd><kwd>DOUBLE-BLIND METHOD</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Poro&#x0111;ajna bol spominje se jo&#x0161; od biblijskih vremena. Povijest poznaje razne na&#x010D;ine obezboljenja poro&#x0111;aja, a u nekim suvremenim dru&#x0161;tvima drevni na&#x010D;ini kupiranja boli poput akupunkture, konzumacije opijata ili primjene ljekovitih biljnih pripravaka i dalje zauzimaju istaknuto mjesto. U suvremenoj ra&#x0111;aonici zlatni je standard epiduralna analgezija, metoda koja i u dana&#x0161;nje vrijeme nije jo&#x0161; dostupna svim rodiljama. Zbog nedostatka optimalnih uvjeta obezboljavanja poro&#x0111;aja epiduralnom analgezijom parenteralna primjena opioida jedna je od prihvatljivih alternativa. Cilj ovog istra&#x017E;ivanja bila je usporedba djelovanja dvaju opioida, tramadola i petidina, tijekom poro&#x0111;aja na opstetri&#x010D;ke ishode.</p>
<sec sec-type="other1">
<title>Metode</title>
<p>Prospektivno usporedbeno (engl. <italic>head-to-head</italic>) randomizirano dvostruko slijepo intervencijsko istra&#x017E;ivanje provedeno je u rodili&#x0161;tu Klinike za &#x017E;enske bolesti i porodni&#x0161;tvo KBC-a Sestre milosrdnice u Zagrebu. Eti&#x010D;ko povjerenstvo odobrilo je istra&#x017E;ivanje. U vrijeme njegova provo&#x0111;enja epiduralna analgezija kao metoda obezboljavanja poro&#x0111;aja nije bila dostupna u rodili&#x0161;tu Klinike za ginekologiju i porodni&#x0161;tvo. Uz pismeni pristanak ispitanice su bile zdrave rodilje neovisno o dobi, podijeljene u dvije skupine metodom restriktivne randomizacije: rodilje kod kojih je primijenjen tramadol i rodilje u kojih je primijenjen petidin. Ampule lijekova numerirane su i upisane bez vidljiva naziva lijeka. Lije&#x010D;nici nisu znali koji su analgetik odabrali niti su rodilje znale koji su analgetik primile. Navedeni lijekovi aplicirani su u dozi od 50 mg intravenski. Tijek poro&#x0111;aja pra&#x0107;en je partogramom prema Friedmanu, a stanje ploda nadzirano kontinuiranim kardiotokografskim zapisom (CTG). Prema smjernicama opstetri&#x010D;ke struke, u slu&#x010D;ajevima prepatolo&#x0161;kog ili patolo&#x0161;kog CTG zapisa izmjeren je stupanj kiselosti fetalne krvi (fetalna pH-metrija). Stanje novoro&#x0111;en&#x010D;eta procijenjeno je nalazom acidobaznog statusa iz krvi pupkovine, a vitalnost neposredno nakon ro&#x0111;enja bodovanjem prema Apgarovoj. Pri respiratornoj depresiji uz odr&#x017E;anu sr&#x010D;anu akciju novoro&#x0111;en&#x010D;eta primijenjen je antidot nalokson u dozi od 0,1 mg/kg. Kriteriji za uklju&#x010D;ivanje ispitanica u istra&#x017E;ivanje bili su: postojanje znakova spasti&#x010D;nog poro&#x0111;aja (uznemirenost, zadebljanje i rigiditet u&#x0161;&#x0107;a maternice, nenapredovanje poro&#x0111;aja unato&#x010D; dobrim trudovima), otvorenost u&#x0161;&#x0107;a od 3 do 7 cm, stav ploda glavom, uredan CTG zapis pri prijmu u trajanju od 20 minuta i pismeni pristanak rodilje. Svaka rodilja s odre&#x0111;enim nalazom otvorenosti u&#x0161;&#x0107;a imala je svoj par u drugoj skupini. U istra&#x017E;ivanje nisu uklju&#x010D;ene rodilje s poznatom preosjetljivo&#x0161;&#x0107;u na opioidne analgetike, bolestima bubrega, jetre, te&#x017E;im sr&#x010D;anim bolestima, znakovima prijete&#x0107;e eklampsije ili s eklampsijom, te&#x017E;im plu&#x0107;nim bolestima, glaukomom, ulceroznim kolitisom, akutnim traumama glave, duljom opstipacijom ili akutnim proljevima, one u stanjima koja nala&#x017E;u primjenu drugih lijekova u poro&#x0111;aju poput psihofarmaka, hormona &#x0161;titne &#x017E;lijezde, cimetidina, tricikli&#x010D;kih antidepresiva, antihipertenzivnih lijekova, u akutnom ili kroni&#x010D;nom pijanstvu, ovisnostima o drogama ili lijekovima, s akutnom i kroni&#x010D;nom respiratornom insuficijencijom posteljice. Iz istra&#x017E;ivanja su isklju&#x010D;ene i rodilje koje su tijekom poro&#x0111;aja odustale od sudjelovanja. Skupine su posebno analizirane s obzirom na trajanje poro&#x0111;aja, subjektivan do&#x017E;ivljaj boli prema numeri&#x010D;koj ljestvici za procjenu boli (VAS od 0 do 10 bodova) prije aplikacije, 10 minuta i 30 minuta poslije aplikacije lijeka, CTG zapis, pojavnost nuspojava nakon primjene lijekova, Apgarin zbroj u novoro&#x0111;en&#x010D;eta u prvoj i petoj minuti nakon ro&#x0111;enja te vrijednosti pH iz njegove pup&#x010D;ane vene. Kao vrijednost standardne devijacije upotrijebljen je teorijski raspon od 30% srednje vrijednosti, &#x0161;to je granica prihvatljive disperzije. Pri analizi podataka slu&#x017E;ili smo se testom razlike u proporcijama dvaju nezavisnih skupova i Studentovim t-testom. Prije provedbe t-testa normalnost je ispitana Kolmogorov-Smirnovljevim testom.</p>
</sec>
<sec sec-type="other2">
<title>Rezultati</title>
<p>Istra&#x017E;ivanjem je obuhva&#x0107;eno 60 rodilja, podijeljenih u dvije skupine ovisno o vrsti primijenjenog opijata. Jedna je skupina od 30 ispitanica primila tramadol, a drugih 30 ispitanica primalo je petidin. Analizom skupina ispitane su razlike u analgetskom u&#x010D;inku, trajanju poro&#x0111;aja, pojavnosti nuspojava, CTG zapisu i neonatalnom ishodu s obzirom na ocjenu vitalnosti novoro&#x0111;en&#x010D;eta prema Apgarovoj i vrijednosti pH iz pup&#x010D;ane vene. Nakon provedenog istra&#x017E;ivanja zabilje&#x017E;ena je ve&#x0107;a u&#x010D;estalost nuspojava u rodilja kod kojih je primijenjen petidin u odnosu prema onima kod kojih je primijenjen tramadol, uz statisti&#x010D;ki zna&#x010D;ajnu povezanost (<xref ref-type="table" rid="t1">Table 1</xref>). Analizom zastupljenosti nuspojava utvrdili smo da je naj&#x010D;e&#x0161;&#x0107;a nuspojava u rodilja kod kojih je primijenjen tramadol bila pospanost, dok je u rodilja kod kojih je primijenjen petidin najzastupljenija bila vrtoglavica (<xref ref-type="table" rid="t1">Table 1</xref>). Statisti&#x010D;ki zna&#x010D;ajno &#x010D;e&#x0161;&#x0107;a bila je pojava vrtoglavice, suho&#x0107;e usta i nesvjestice u rodilja kod kojih je primijenjen petidin, dok je pospanost bila statisti&#x010D;ki zna&#x010D;ajno &#x010D;e&#x0161;&#x0107;a pojava u rodilja koje su primile tramadol (<xref ref-type="table" rid="t1">Table 1</xref>). Neke su pacijentice imale vi&#x0161;e nuspojava.</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Comparison of adverse effects in mothers following administration of tramadol and pethidine (difference of proportion)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="20.73%"/>
<col width="17.15%"/>
<col width="15.38%"/>
<col width="7.69%"/>
<col width="20.12%"/>
<col width="18.93%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nuspojave<break/>/ Adverse effects</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">tramadol / Tramadol<break/>(N = 30)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">petidin / Pethidine<break/>(N = 30)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">P</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">CI<break/>tramadol / Tramadol (%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">CI<break/>petidin / Pethidine (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Bez / Without adverse effects (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">46,20</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,00</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&lt; 0,001</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">18,15%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,00%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Vrtoglavica / Dizziness (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,00</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">37,50</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&lt; 0,001</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,00%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">17,62%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Povra&#x0107;anje / Vomiting (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,69</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">18,75</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,206</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">9,7%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">14,21%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Suho&#x0107;a usta / Dryness of mouth (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,00</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">18,75</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,013</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,00%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">14,21%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Mu&#x010D;nina / Nausea (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,69</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">18,75</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,206</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">9,70%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">14,21%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Zamu&#x0107;enost vida / Blurred vision (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,69</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">14,20</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,419</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">9,7%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">12,70%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Pospanost / Drowsiness (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">38,30</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12,50</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,022</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">17,69%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">12,04%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Svrbe&#x017E; / Itching (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,00</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">6,25</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,164</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,00%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">8,81%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Nesvjestica / Fainting (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,00</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">12,50</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,046</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,00%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">12,04%</td>
</tr>
</tbody></table></table-wrap>
<p>Statisti&#x010D;ki zna&#x010D;ajno ni&#x017E;a vrijednost boli nakon 10 minuta i 30 minuta utvr&#x0111;ena je u pacijentica kod kojih je upotrijebljen petidin (<xref ref-type="table" rid="t2">Table 2</xref>).</p>
<table-wrap id="t2" position="float">
<label>Table 2</label><caption><title>Mean difference in pain 10 and 30 minutes after drug application (Student&#x2019;s t-test)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="27.85%"/>
<col width="17.15%"/>
<col width="15.38%"/>
<col width="7.09%"/>
<col width="17.15%"/>
<col width="15.38%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">tramadol / Tramadol<break/>(N = 30)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">petidin / Pethidine<break/>(N = 30)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">p</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">CI<break/>tramadol / Tramadol (%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">CI<break/>petidin / Pethidine (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">10 min nakon apliciranja lijeka<break/>/ 10 min after drug application</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-0,92<break/>(0,28)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-1,650 (0,50)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&lt; 0,001</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,100</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,180</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">30 min nakon apliciranja lijeka<break/>/ 30 min after drug application</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,62<break/>(0,19)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">-0,700 (0,21)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">&lt; 0,001</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,068</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">0,076</td>
</tr>
</tbody></table></table-wrap>
<p>U obje promatrane to&#x010D;ke mjerenja utvr&#x0111;ena je negativna razlika boli u pacijentica kod kojih je primijenjen petidin, dok je ve&#x0107; nakon 30 minuta efekt primjene tramadola i&#x0161;&#x010D;eznuo (pozitivna razlika osjeta boli u odnosu prema po&#x010D;etnom mjerenju) (<xref ref-type="table" rid="t2">Table 2</xref>). Nije utvr&#x0111;ena statisti&#x010D;ki zna&#x010D;ajna razlika u u&#x010D;estalosti ranih deceleracija (DIP 1) na CTG zapisu, su&#x017E;ene undulacije, kasnih deceleracija (DIP 2) ili silentnog CTG zapisa izme&#x0111;u promatranih skupina (<xref ref-type="table" rid="t3">Table 3</xref>). U novoro&#x0111;en&#x010D;adi obje promatrane skupine nije bilo statisti&#x010D;ke zna&#x010D;ajne razlike u vrijednostima Apgarina zbroja (<xref ref-type="table" rid="t4">Table 4</xref>), kao ni u vrijednostima pH iz pupkovine (<xref ref-type="table" rid="t5">Table 5</xref>). Statisti&#x010D;ki zna&#x010D;ajno dulje trajanje poro&#x0111;aja zabilje&#x017E;eno je nakon primjene petidina u odnosu prema tramadolu (<xref ref-type="table" rid="t6">Table 6</xref>).</p>
<table-wrap id="t3" position="float">
<label>Table 3</label><caption><title>Comparison of continuous cardiotocography characteristics after administration of tramadol and pethidine (difference in proportions test)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="27.85%"/>
<col width="17.15%"/>
<col width="15.38%"/>
<col width="7.09%"/>
<col width="17.15%"/>
<col width="15.38%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">tramadol / Tramadol<break/>(N = 30)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">petidin / Pethidine<break/>(N = 30)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">p</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">CI<break/>tramadol / Tramadol<break/>(%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">CI<break/>petidin / Pethidine<break/>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">U&#x010D;estalost DIP I i su&#x017E;ene undulacije<break/>/ Frequency of early decelerations and minimal variability (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,70</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12,50</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,537</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">9,70%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">12,04%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">U&#x010D;estalost silentnog tipa CTG zapisa i DIP II / Frequency of absent variability and late decelerations (%)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,00</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">6,25</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,164</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,00%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">8,81%</td>
</tr>
</tbody></table></table-wrap>
<table-wrap id="t4" position="float">
<label>Table 4</label><caption><title>Comparison of Apgar after administration of tramadol and pethidine (Student&#x2019;s t-Test)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="27.85%"/>
<col width="17.15%"/>
<col width="15.38%"/>
<col width="7.09%"/>
<col width="17.15%"/>
<col width="15.38%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">tramadol / Tramadol<break/>(N = 30)<break/>(SD)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">petidin / Pethidine<break/>(N = 30)<break/>(SD)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">p</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">CI<break/>tramadol / Tramadol<break/>(%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">CI<break/>petidin / Pethidine<break/>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Apgarin zbroj u prvoj minuti nakon ro&#x0111;enja / Apgar score after 1 min</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">8,69<break/>(2,61)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">8,53<break/>(2,56)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,811</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,009</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,009</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Apgarin zbroj u petoj minuti nakon ro&#x0111;enja / Apgar score after 5 min</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">9,54<break/>(2,86)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">9,40<break/>(2,82)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,849</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,010</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">0,010</td>
</tr>
</tbody></table></table-wrap>
<table-wrap id="t5" position="float">
<label>Table 5</label><caption><title>Comparison of umbilical venous blood pH (Student&#x2019;s t-Test)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="23.11%"/>
<col width="18.34%"/>
<col width="16.56%"/>
<col width="7.09%"/>
<col width="18.34%"/>
<col width="16.56%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">tramadol / Tramadol<break/>(N = 30)<break/>(SD)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">petidin / Pethidine<break/>(N = 30)<break/>(SD)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">p</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">CI<break/>tramadol / Tramadol<break/>(%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">CI<break/>petidin / Pethidine<break/>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">pH</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">7,32 (2,2)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">7,29 (2,19)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,958</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,799</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">0,796</td>
</tr>
</tbody></table></table-wrap>
<table-wrap id="t6" position="float">
<label>Table 6</label><caption><title>Duration of labor after administration of tramadol and pethidine (Student&#x2019;s t-Test)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="23.11%"/>
<col width="18.34%"/>
<col width="16.56%"/>
<col width="7.09%"/>
<col width="18.34%"/>
<col width="16.56%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"></th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">tramadol / Tramadol<break/>(N = 30)<break/>(SD)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">petidin / Pethidine<break/>(N = 30)<break/>(SD)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">p</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">CI<break/>tramadol / Tramadol<break/>(%)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">CI<break/>petidin / Pethidine<break/>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Trajanje poro&#x0111;aja u satima / Duration of labor</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">6,16 (1,85)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">7,53 (2,26)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,013</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">0,67</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">0,67</td>
</tr>
</tbody></table></table-wrap>
</sec>
<sec sec-type="other3">
<title>Rasprava</title>
<p>Poznavanje slo&#x017E;enosti i interakcije razli&#x010D;itih aspekata bolnog do&#x017E;ivljaja mo&#x017E;e pomo&#x0107;i u pristupu trudnici i uklanjanju boli. Nociceptivna, kognitivno-bihevioralna i afektivno-motivacijska najva&#x017E;nije su dimenzije boli pri poro&#x0111;aju. Nociceptivni bolni podra&#x017E;aj za vrijeme drugoga poro&#x0111;ajnog doba zbog rastezanja tkiva poro&#x0111;ajnog kanala osnovni je neurofiziolo&#x0161;ki mehanizam boli u poro&#x0111;aju. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) U integraciji percepcije i stvaranja negativnog do&#x017E;ivljaja boli zasnovanog na prethodnim iskustvima i emocijama sudjeluju veze limbi&#x010D;kih struktura mozga s korteksom i opisuju afektivno-motivacijsku dimenziju boli. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Pri procjeni kvalitete boli kod svake rodilje potrebno je imati na umu i razli&#x010D;ite na&#x010D;ine individualne ekspresije neugode, tj. kognitivno-bihevioralne dimenzije boli. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) Bez obzira na prethodno opisane spoznaje o boli, intenzivna neugoda pri poro&#x0111;aju &#x010D;esto je pra&#x0107;ena strahom. Aktivacija simpati&#x010D;koga &#x017E;iv&#x010D;anog sustava i porast razine cirkuliraju&#x0107;ih katekolamina u stanjima boli i straha smanjuju protok krvi kroz posteljicu, a hiperventilacija majke s posljedi&#x010D;nom hipokarbijom i pomicanjem krivulje oksihemoglobina ulijevo ometa dostatnu opskrbu fetusa kisikom i poja&#x010D;ava do&#x017E;ivljaj boli. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Zbog toga je po&#x017E;eljan terapijski pristup usmjeren prema prepoznavanju razli&#x010D;itih dimenzija boli i uklanjanju straha i patnje, uz istodobno osiguranje urednog tijeka poro&#x0111;aja. Nefarmakolo&#x0161;ke metode ubla&#x017E;avanja boli, temeljene na endogenim mehanizmima modulacije boli, zasad nisu op&#x0107;eprihva&#x0107;ene u klini&#x010D;kom radu. U modernoj ra&#x0111;aonici prednost se daje narkoticima, sedativima i spazmoliticima. Epiduralna analgezija naju&#x010D;inkovitija je metoda obezboljavanja poro&#x0111;aja. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) Kad epiduralna analgezija nije dostupna, kao &#x0161;to je to bilo u rodili&#x0161;tu Klinike tijekom provo&#x0111;enja ovog istra&#x017E;ivanja, a u &#x017E;elji za brzom i u&#x010D;inkovitom analgezijom u vrijeme jake boli i intenzivnih trudova, izbor je parenteralna primjena opioida. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Kupiranje boli posti&#x017E;e se primjenom pojedina&#x010D;nih doza opioida, koje se mogu i ponoviti ovisno o &#x017E;eljenom stupnju kontrole boli. Bolja kontrola boli uz smanjenje ne&#x017E;eljenih u&#x010D;inaka mo&#x017E;e se posti&#x0107;i i primjenom trajnih intravenskih pumpa. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Prijenos opioida preko posteljice zbiva se pasivnom difuzijom. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) U odraslih se eliminacija opioida uvelike posti&#x017E;e konjugacijom s glukuronidima u jetri. Jedan od naj&#x010D;e&#x0161;&#x0107;e propisanih opioidnih analgetika za ubla&#x017E;avanje umjerene do jake boli pri poro&#x0111;aju jest petidin, sintetski derivat s farmakolo&#x0161;kim u&#x010D;inkom sli&#x010D;nim morfinu, u anglosaskoj literaturi poznat kao meperidin. Metabolizam petidina u jetri zbiva se N-demetilacijom u norpetidin. Ne&#x017E;eljena djelovanja petidina jesu pospanost, zamu&#x0107;enost vida, retencija urina, suho&#x0107;a usta, mu&#x010D;nina, povra&#x0107;anje, a svojstvo norpetidina kod visokih doza petidina jest i halucinogeni i konvulzivni u&#x010D;inak. Osim depresije disanja, mogu&#x0107;e posljedice u novoro&#x0111;en&#x010D;adi jesu hipotermija, problemi s hranjenjem, su&#x017E;eno stanje svijesti. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) U sustavnom pregledu literature koji su proveli Bricker i Lavender, a uklju&#x010D;ivao je analizu intravenske, intramuskularne i epiduralne analgezije, paracervikalnog bloka i metode analgezije koju kontrolira pacijentica za vrijeme poro&#x0111;aja, ne postoje jasni dokazi o prednosti jednog od opioida (tramadol, meptazinol, dijamorfin, pentazocin, nalbufin, butorfanol, morfij i fentanil) u odnosu prema petidinu s obzirom na neonatalni ishod. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>)</p>
<p>Zbog mogu&#x0107;ega ja&#x010D;eg djelovanja petidina na majku u obliku pospanosti, ali i depresije disanja u novoro&#x0111;en&#x010D;adi, njegova uloga u ubla&#x017E;avanju poro&#x0111;ajne boli i dalje je predmet istra&#x017E;ivanja. U&#x010D;inak depresije disanja u novoro&#x0111;en&#x010D;eta najuo&#x010D;ljiviji je ako je poro&#x0111;aj dovr&#x0161;en dva do tri sata nakon intravenske primjene lijeka. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Aktivni metabolit normeperidin djeluje na centar za disanje i sr&#x010D;anu akciju fetusa, fetalno pona&#x0161;anje i prihva&#x0107;anje dojenja. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>&#x2013;<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Slijedom navedenoga potrebno je razmotriti primjenu drugih, u&#x010D;inkovitijih lijekova s povoljnijim analgetskim u&#x010D;inkom i opstetri&#x010D;kim ishodima. U odnosu prema petidinu naj&#x010D;e&#x0161;&#x0107;e rabljeni opioidni analgetik jest tramadol. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) To je slabi agonist u-opioidnih receptora i slabi inhibitor unosa noradrenalina. Prednost tramadola u odnosu prema petidinu jest da ne izaziva depresiju disanja. Unato&#x010D; slabijem analgetskom u&#x010D;inku tramadola primjena kombinirane epiduralne/spinalne analgezije, kao i epiduralne analgezije koju kontrolira pacijentica (PCEA) te intravenske analgezije &#x0161;to ju kontrolira pacijentica (PCIA) s tramadolom znatno skra&#x0107;uje drugo poro&#x0111;ajno doba, a bez va&#x017E;nijeg utjecaja na sr&#x010D;anu akciju djeteta. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Metabolizam tramadola zbiva se preko citokrom-oksidaza, enzimima CYP2D6 i CYP3A4, zbog &#x010D;ega kod osoba s poja&#x010D;anom ili oslabljenom funkcijom enzima postoje i razlike u analgetskom u&#x010D;inku i pojavnosti nuspojava. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) Osobe koje su brzi metabolizatori imaju slabiji odgovor na lijek, ali i manje ne&#x017E;eljenih reakcija. Prema rezultatima farmakogeneti&#x010D;kog istra&#x017E;ivanja koje je provedeno u Hrvatskoj istodobno kad i na&#x0161;e istra&#x017E;ivanje, u&#x010D;estalost fenotipa slabih metabolizatora supstrata CYP2D6 iznosila je 3%, a brzih metabolizatora 4%. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>)</p>
<p>U izvje&#x0161;&#x0107;u Svjetske zdravstvene organizacije iz 2018. godine navedeni su rezultati 6 studija koje su uspore&#x0111;ivale ishode nakon intramuskularne primjene tramadola i petidina u poro&#x0111;aju. Objavljeni su rezultati istra&#x017E;ivanja provedenih na ukupno 483 ispitanice. Usporedbom rezultata istra&#x017E;ivanja koja su ispitivala intramuskularnu primjenu tramadola i petidina utvr&#x0111;eno je da ne postoje sigurni dokazi o prednosti jednog od dvaju lijekova s obzirom na analgetski u&#x010D;inak, na&#x010D;in dovr&#x0161;enja poro&#x0111;aja, nuspojave u obliku pospanosti i povra&#x0107;anja, Apgarinog zbroja u novoro&#x0111;en&#x010D;adi i pojavnosti njihova respiratornog distresa. Stoga, a na temelju analize podataka o intramuskularnoj primjeni lijeka, u preporukama Svjetske zdravstvene organizacije iz 2018. primjena tramadola nije navedena. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) U kontekstu usporedbe primjene tramadola s primjenom neopioidnih analgetika pri poro&#x0111;aju, godine 2014. objavljeno je istra&#x017E;ivanje na uzorku od 200 rodilja koje je uspore&#x0111;ivalo analgetski u&#x010D;inak tramadola i paracetamola i dokazalo da je paracetamol u dozi od 1000 mg intravenski imao znatno bolji analgetski u&#x010D;inak uz kra&#x0107;e trajanje poro&#x0111;aja te manju pojavnost nuspojava poput mu&#x010D;nine i povra&#x0107;anja u odnosu prema tramadolu primijenjenom u dozi od 100 mg intramuskularno. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) Iako je donedavno prevladavalo mi&#x0161;ljenje da paracetamol ne utje&#x010D;e na zatvaranje arterijskog duktusa u novoro&#x0111;en&#x010D;adi, novija klini&#x010D;ka istra&#x017E;ivanja pokazuju kako paracetamol u dozi od 15 mg/kg tjelesne te&#x017E;ine novoro&#x0111;en&#x010D;eta tijekom tri dana u&#x010D;inkovito zatvara arterijski duktus. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>&#x2013;<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) S obzirom na navedeno, preostaje ispitati ulogu i analgetski u&#x010D;inak tramadola u poro&#x0111;aju, kao i djelovanje na neonatalni ishod. U velikom dijelu radova koji su analizirali analgetski u&#x010D;inak tramadola tijekom poro&#x0111;aja, doza tramadola bila je 100 mg ili 1 mg/kg primijenjena intramuskularno. Malen je broj radova koji su uspore&#x0111;ivali minimalne doze, obje primijenjene intravenski. U na&#x0161;em je slu&#x010D;aju intravenska primjena bila po&#x017E;eljnija s obzirom na jednostavnost primjene lijeka i br&#x017E;e djelovanje. &#x017D;ari&#x0161;te interesa bila je analiza primjene minimalne po&#x010D;etne doze. Rezultati na&#x0161;eg istra&#x017E;ivanja pokazali su znatno kra&#x0107;e trajanje poro&#x0111;aja u rodilja nakon primjene tramadola u odnosu prema petidinu i podudaraju se sa zaklju&#x010D;cima istra&#x017E;ivanja Maryam Khooshideh o ulozi ovih dvaju analgetika u poro&#x0111;aju. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Za razliku od Khooshidehina istra&#x017E;ivanja, u kojemu je srednje vrijeme trajanja poro&#x0111;aja bilo 4 sata nakon primjene tramadola, (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) dovr&#x0161;etak poro&#x0111;aja u na&#x0161;em istra&#x017E;ivanju bio je u roku od 6,16 sati. Dulje srednje vrijeme trajanja poro&#x0111;aja zabilje&#x017E;eno je u istra&#x017E;ivanju Viegasa i suradnika i iznosilo je 7,9 sati. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Isto tako, dulje trajanje poro&#x0111;aja zabilje&#x017E;eno je i u Hussleinovoj studiji, no bez dokazane statisti&#x010D;ke zna&#x010D;ajnosti. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) Testiranjem djelovanja petidina na glatku muskulaturu uterusa mi&#x0161;eva pokazano je da petidin u aktivnoj fazi poro&#x0111;aja pove&#x0107;ava kontraktilnost mi&#x0161;i&#x0107;a uterusa i mo&#x017E;e biti razlog kra&#x0107;eg trajanja poro&#x0111;aja. Na histolo&#x0161;kim preparatima tkiva uterusa rodilja, dobivenog carskim rezom, dokazan je suprotni efekt petidina. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) Za razliku od petidina, studija o u&#x010D;inku tramadola na kontraktilnost uterine muskulature ze&#x010D;eva u poro&#x0111;aju pokazala je stimuliraju&#x0107;i efekt na tkivo uterusa u obliku pove&#x0107;anja amplitude i trajanja kontrakcije, bez u&#x010D;inka na u&#x010D;estalost kontrakcija. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>) Analiza ne&#x017E;eljenih u&#x010D;inaka pokazala je da je u&#x010D;estalost nuspojava bila ve&#x0107;a u skupini ispitanica koje su primale petidin. U na&#x0161;em istra&#x017E;ivanju naj&#x010D;e&#x0161;&#x0107;a nuspojava u rodilja nakon primjene tramadola bila je pospanost, a u rodilja kod kojih je primijenjen petidin vrtoglavica. U literaturi se spominje manja u&#x010D;estalost mu&#x010D;nine, povra&#x0107;anja i pospanosti nakon primjene tramadola u odnosu prema petidinu iako postoje i suprotni zaklju&#x010D;ci. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="r24"><italic>24</italic></xref>, <xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) Keskin i suradnici u svojem su radu dokazali ve&#x0107;u u&#x010D;estalost mu&#x010D;nine i pospanosti nakon primjene tramadola u odnosu prema petidinu. (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) U na&#x0161;em istra&#x017E;ivanju statisti&#x010D;ki zna&#x010D;ajno manja bila je u&#x010D;estalost vrtoglavice, suho&#x0107;e usta i nesvjestice u rodilja kod kojih je primijenjen tramadol. Iako je poro&#x0111;aj trajao dulje, statisti&#x010D;ki zna&#x010D;ajno manja bol utvr&#x0111;ena je u pacijentica koje su primale petidin, dok je efekt primjene tramadola i&#x0161;&#x010D;eznuo nakon 30 minuta (pozitivna razlika osjeta boli u odnosu prema po&#x010D;etnom mjerenju). Nedostatak ove studije koji utje&#x010D;e na interpretaciju rezultata jest &#x010D;injenica da nisu istaknute razine VAS-a prije i poslije primjene lijeka. U istra&#x017E;ivanju smo pratili objektivne znakove spasti&#x010D;nog poro&#x0111;aja (uznemirenost trudnice, zadebljanje i rigiditet u&#x0161;&#x0107;a maternice, nenapredovanje poro&#x0111;aja unato&#x010D; dobrim trudovima), a razlikama vrijednosti prema VAS-u pra&#x0107;en je subjektivan do&#x017E;ivljaj boli. Budu&#x0107;a istra&#x017E;ivanja trebala bi usporediti po&#x010D;etni i kona&#x010D;ni subjektivan do&#x017E;ivljaj boli prema VAS-u. Analizom CTG zapisa za vrijeme poro&#x0111;aja nije utvr&#x0111;ena statisti&#x010D;ki zna&#x010D;ajna razlika pojavnosti prepatolo&#x0161;kog ili patolo&#x0161;kog CTG zapisa. Prema na&#x0161;em istra&#x017E;ivanju, neposredno nakon ro&#x0111;enja, u prvoj i petoj minuti, srednje vrijednosti Apgarina zbroja u novoro&#x0111;en&#x010D;adi majka koje su primale tramadol bile su vi&#x0161;e nego u novoro&#x0111;en&#x010D;adi majka koje su primale petidin, ali bez statisti&#x010D;ki zna&#x010D;ajne razlike. Srednje vrijednosti Apgarina zbroja nakon primjene tramadola iznosile su 8,69 &#x00B1; 2,61 u prvoj minuti te 9,54 &#x00B1; 2,86 u petoj minuti poslije ro&#x0111;enja, &#x0161;to je vi&#x0161;e od srednjih vrijednosti 8 (+ 1,7) i 9,1 (+ 1,2) koje navode Hedi Claahsen-van der Grinten i suradnici, (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>) dok statisti&#x010D;ki zna&#x010D;ajne razlike nisu zabilje&#x017E;ene u studiji Keskina i suradnika. (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>)</p>
<p>Pri analizi dviju vrsta opioidnih analgetika nije utvr&#x0111;ena statisti&#x010D;ki zna&#x010D;ajna razlika u vrijednosti pH iz pup&#x010D;ane vene.</p>
</sec>
<sec sec-type="other4">
<title>Zaklju&#x010D;ak</title>
<p>Oba primijenjena opioidna analgetika imaju prednosti i nedostatke. Tramadol skra&#x0107;uje trajanje poro&#x0111;aja, a petidin ima ja&#x010D;i analgetski u&#x010D;inak, ali i vi&#x0161;e neugodnih nuspojava za majku. Neonatalni je ishod neovisan o vrsti opioida. Zato je u klini&#x010D;koj praksi potrebno individualizirati pristup rodiljama i odlu&#x010D;iti se za opioid koji nam u danom trenutku u&#x010D;inkovitije poma&#x017E;e pri vo&#x0111;enju poro&#x0111;aja. &#x017D;elimo li bolji analgetski u&#x010D;inak, upotrijebit &#x0107;emo petidin, a ako &#x017E;elimo skratiti poro&#x0111;aj, odlu&#x010D;it &#x0107;emo se za tramadol.</p>
<p>Svi postupci u ovom istra&#x017E;ivanju provedeni su sukladno eti&#x010D;kim standardima institucijskog odbora odgovornog za izvo&#x0111;enje istra&#x017E;ivanja na ljudima i u skladu su s Helsin&#x0161;kom deklaracijom iz 1975. godine, revidiranom 1983. godine.</p>
</sec>
</body>
<back>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonapace</surname><given-names>J</given-names></name><name><surname>Gagn&#x00E9;</surname><given-names>GP</given-names></name><name><surname>Chaillet</surname><given-names>N</given-names></name><name><surname>Gagnon</surname><given-names>R</given-names></name><name><surname>H&#x00E9;bert</surname><given-names>E</given-names></name><name><surname>Buckley</surname><given-names>S</given-names></name></person-group>. <article-title>No. 355-Physiologic Basis of Pain in Labour and Delivery: An Evidence-Based Approach to its Management.</article-title> <source>J Obstet Gynaecol Can</source>. <year>2018</year>;<volume>40</volume>:<fpage>227</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.jogc.2017.08.003</pub-id><pub-id pub-id-type="pmid">29447711</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name></person-group>. <article-title>A new perspective on the anterior cingulate cortex and affective pain.</article-title> <source>Neurosci Biobehav Rev</source>. <year>2018</year>;<volume>90</volume>:<fpage>200</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.03.022</pub-id><pub-id pub-id-type="pmid">29698697</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labor</surname><given-names>S</given-names></name><name><surname>Maguire</surname><given-names>S</given-names></name></person-group>. <article-title>The pain of labour.</article-title> <source>Rev Pain</source>. <year>2008</year>;<volume>2</volume>:<fpage>15</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1177/204946370800200205</pub-id><pub-id pub-id-type="pmid">26526404</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kranke</surname><given-names>P</given-names></name><name><surname>Weibel</surname><given-names>S</given-names></name></person-group>. <article-title>Pain relief during labour: challenging the use of intramuscular pethidine.</article-title> <source>Lancet</source>. <year>2018</year>;<volume>392</volume>:<fpage>617</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31717-3</pub-id><pub-id pub-id-type="pmid">30115485</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anim&#x2010;Somuah</surname><given-names>M</given-names></name><name><surname>Smyth</surname><given-names>RM</given-names></name><name><surname>Cyna</surname><given-names>AM</given-names></name><name><surname>Cuthbert</surname><given-names>A</given-names></name></person-group>. <article-title>Epidural versus non&#x2010;epidural or no analgesia for pain management in labour.</article-title> <source>Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>5</volume>:<elocation-id>CD000331</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD000331.pub4</pub-id><pub-id pub-id-type="pmid">29781504</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Arya</surname><given-names>VK</given-names></name><name><surname>Gopalan</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>V</given-names></name></person-group>. <article-title>Analgesic efficacy of intramuscular opioids versus epidural analgesia in labor.</article-title> <source>Int J Gynaecol Obstet</source>. <year>2003</year>;<volume>83</volume>:<fpage>19</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/S0020-7292(03)00201-7</pub-id><pub-id pub-id-type="pmid">14511868</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnabel</surname><given-names>A</given-names></name><name><surname>Hahn</surname><given-names>N</given-names></name><name><surname>Broscheit</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Remifentanil for labour analgesia: a meta-analysis of randomised controlled trials.</article-title> <source>Eur J Anaesthesiol</source>. <year>2012</year>;<volume>29</volume>:<fpage>177</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1097/EJA.0b013e32834fc260</pub-id><pub-id pub-id-type="pmid">22273829</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>SK</given-names></name><name><surname>Campbell</surname><given-names>JP</given-names></name></person-group>. <article-title>Placental structure, function and drug transfer.</article-title> <source>Anaesth Crit Care Pain</source>. <year>2014</year>;<volume>15</volume>:<fpage>84</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/bjaceaccp/mku013</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>F</given-names></name></person-group>. <article-title>The effects of maternal labour analgesia on the fetus.</article-title> <source>Best Pract Res Clin Obstet Gynaecol</source>. <year>2010</year>;<volume>24</volume>:<fpage>289</fpage>&#x2013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2009.11.003</pub-id><pub-id pub-id-type="pmid">20005180</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bricker</surname><given-names>L</given-names></name><name><surname>Lavender</surname><given-names>T</given-names></name></person-group>. <article-title>Parenteral opioids for labor pain relief: a systematic review.</article-title> <source>Am J Obstet Gynecol</source>. <year>2002</year>;<volume>186</volume>:<fpage>S94</fpage>&#x2013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9378(02)70185-3</pub-id><pub-id pub-id-type="pmid">12011876</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrie</surname><given-names>RH</given-names></name><name><surname>Yeh</surname><given-names>SY</given-names></name><name><surname>Murata</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>The effect of drugs on fetal heart rate variability.</article-title> <source>Am J Obstet Gynecol</source>. <year>1978</year>;<volume>130</volume>:<fpage>294</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23679</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattingly</surname><given-names>JE</given-names></name><name><surname>D&#x2019;Alessio</surname><given-names>J</given-names></name><name><surname>Ramanathan</surname><given-names>J</given-names></name></person-group>. <article-title>Effects of obstetric analgesics and anesthetics on the neonate.</article-title> <source>Paediatr Drugs</source>. <year>2003</year>;<volume>5</volume>:<fpage>615</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.2165/00148581-200305090-00004</pub-id><pub-id pub-id-type="pmid">12956618</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khooshideh</surname><given-names>M</given-names></name><name><surname>Shahriari</surname><given-names>A</given-names></name></person-group>. <article-title>A comparison of tramadol and pethidine analgesia on the duration of labour: a randomised clinical trial.</article-title> <source>Aust N Z J Obstet Gynaecol</source>. <year>2009</year>;<volume>49</volume>:<fpage>59</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1111/j.1479-828X.2009.00949.x</pub-id><pub-id pub-id-type="pmid">19281581</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fieni</surname><given-names>S</given-names></name><name><surname>Angeri</surname><given-names>F</given-names></name><name><surname>Kaihura</surname><given-names>CT</given-names></name><etal/></person-group> <article-title>Evaluation of the peripartum effects of 2 analgesics: meperidine and tramadol, used in labor.</article-title> <source>Acta Biomed Ateneo Parmense</source>. <year>2000</year>;<volume>71</volume>:<fpage>397</fpage>&#x2013;<lpage>400</lpage>.<pub-id pub-id-type="pmid">11424777</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name></person-group>. <article-title>Patient controlled intravenous analgesia with tramadol for labor pain relief.</article-title> <source>Chin Med J (Engl)</source>. <year>2003</year>;<volume>116</volume>(<issue>11</issue>):<fpage>1752</fpage>&#x2013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">14642152</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miotto</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>AK</given-names></name><name><surname>Khalil</surname><given-names>MA</given-names></name><name><surname>Blanco</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>JD</given-names></name><name><surname>Rawson</surname><given-names>R</given-names></name></person-group>. <article-title>Trends in tramadol: pharmacology, metabolism, and misuse.</article-title> <source>Anesth Analg</source>. <year>2017</year>;<volume>124</volume>:<fpage>44</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1213/ANE.0000000000001683</pub-id><pub-id pub-id-type="pmid">27861439</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozina</surname><given-names>N</given-names></name><name><surname>Grani&#x0107;</surname><given-names>P</given-names></name><name><surname>Lali&#x0107;</surname><given-names>Z</given-names></name><name><surname>Tramisak</surname><given-names>I</given-names></name><name><surname>Lovri&#x0107;</surname><given-names>M</given-names></name><name><surname>Stavljeni&#x0107;-Rukavina</surname><given-names>A</given-names></name></person-group>. <article-title>Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.</article-title> <source>Croat Med J</source>. <year>2003</year>;<volume>44</volume>:<fpage>425</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12950145</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="web">World Health Organization. WHO recommendation on opioid analgesia for pain relief during labour. Geneva: WHO, 2018. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/care-during-childbirth/care-during-labour-1st-stage/who-recommendation-opioid-analgesia-pain-relief-during-labour">https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/care-during-childbirth/care-during-labour-1st-stage/who-recommendation-opioid-analgesia-pain-relief-during-labour</ext-link>. Pristupljeno: 18. prosinca 2019.</mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lallar</surname><given-names>M</given-names></name><name><surname>Anam</surname><given-names>HU</given-names></name><name><surname>Nandal</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Katyal</surname><given-names>S</given-names></name></person-group>. <article-title>Intravenous paracetamol infusion versus intramuscular tramadol as an intrapartum labor analgesic.</article-title> <source>J Obstet Gynaecol India</source>. <year>2015</year>;<volume>65</volume>:<fpage>17</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1007/s13224-014-0556-x</pub-id><pub-id pub-id-type="pmid">25737617</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohlsson</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name></person-group>. <article-title>Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.</article-title> <source>Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>4</volume>:<elocation-id>CD010061</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD010061.pub3</pub-id><pub-id pub-id-type="pmid">29624206</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammerman</surname><given-names>C</given-names></name><name><surname>Bin-Nun</surname><given-names>A</given-names></name><name><surname>Markovitch</surname><given-names>E</given-names></name><name><surname>Schimmel</surname><given-names>MS</given-names></name><name><surname>Kaplan</surname><given-names>M</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name></person-group>. <article-title>Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment.</article-title> <source>Pediatrics</source>. <year>2011</year>;<volume>128</volume>:<fpage>e1618</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2011-0359</pub-id><pub-id pub-id-type="pmid">22065264</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur Makkar</surname><given-names>J</given-names></name><name><surname>Jain</surname><given-names>K</given-names></name><name><surname>Bhatia</surname><given-names>N</given-names></name><name><surname>Jain</surname><given-names>V</given-names></name><name><surname>Mal Mithrawal</surname><given-names>S</given-names></name></person-group>. <article-title>Comparison of analgesic efficacy of paracetamol and tramadol for pain relief in active labor.</article-title> <source>J Clin Anesth</source>. <year>2015</year>;<volume>27</volume>:<fpage>159</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinane.2014.08.008</pub-id><pub-id pub-id-type="pmid">25434500</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oncel</surname><given-names>MY</given-names></name><name><surname>Yurttutan</surname><given-names>S</given-names></name><name><surname>Erdeve</surname><given-names>O</given-names></name><etal/></person-group> <article-title>Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.</article-title> <source>J Pediatr</source>. <year>2014</year>;<volume>164</volume>:<fpage>510</fpage>&#x2013;<lpage>4.e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2013.11.008</pub-id><pub-id pub-id-type="pmid">24359938</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viegas</surname><given-names>OA</given-names></name><name><surname>Khaw</surname><given-names>B</given-names></name><name><surname>Ratnam</surname><given-names>SS</given-names></name></person-group>. <article-title>Tramadol in labour pain in primiparous patients. A prospective comparative clinical trial.</article-title> <source>Eur J Obstet Gynecol Reprod Biol</source>. <year>1993</year>;<volume>49</volume>:<fpage>131</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/0028-2243(93)90260-J</pub-id><pub-id pub-id-type="pmid">8405626</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husslein</surname><given-names>P</given-names></name><name><surname>Kubista</surname><given-names>E</given-names></name><name><surname>Egarter</surname><given-names>C</given-names></name></person-group>. <article-title>Obstetrical analgesia with tramadol &#x2013; Results of a prospective randomized comparative study with pethidine.</article-title> <source>Z Geburtshilfe Perinatol</source>. <year>1987</year>;<volume>191</volume>:<fpage>234</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">3331863</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>KY</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Jeong</surname><given-names>SW</given-names></name></person-group>. <article-title>The effects of opioids on isolated human pregnant uterine muscles.</article-title> <source>Anesth Analg</source>. <year>2001</year>;<volume>92</volume>:<fpage>1006</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00000539-200104000-00037</pub-id><pub-id pub-id-type="pmid">11273940</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakovleva</surname><given-names>AA</given-names></name><name><surname>Nazarova</surname><given-names>LA</given-names></name><name><surname>Prokopenko</surname><given-names>VM</given-names></name><name><surname>Pavlova</surname><given-names>NG</given-names></name></person-group>. <article-title>Effect of Tramadol on Rabbit Uterine Contractile Activity Induced in Late Pregnancy.</article-title> <source>Bull Exp Biol Med</source>. <year>2017</year>;<volume>162</volume>:<fpage>349</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/s10517-017-3613-5</pub-id><pub-id pub-id-type="pmid">28091908</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keskin</surname><given-names>HL</given-names></name><name><surname>Aktepe Keskin</surname><given-names>E</given-names></name><name><surname>Avsar</surname><given-names>AF</given-names></name><name><surname>Tabuk</surname><given-names>M</given-names></name><name><surname>Caglar</surname><given-names>GS</given-names></name></person-group>. <article-title>Pethidine versus tramadol for pain relief during labor.</article-title> <source>Int J Gynaecol Obstet</source>. <year>2003</year>;<volume>82</volume>:<fpage>11</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0020-7292(03)00047-X</pub-id><pub-id pub-id-type="pmid">12834936</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claahsen-van der Grinten</surname><given-names>HL</given-names></name><name><surname>Verbruggen</surname><given-names>I</given-names></name><name><surname>Van Den Berg</surname><given-names>PP</given-names></name><name><surname>Sporken</surname><given-names>JM</given-names></name><name><surname>Kollee</surname><given-names>LA</given-names></name></person-group>. <article-title>Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates.</article-title> <source>Eur J Clin Pharmacol</source>. <year>2005</year>;<volume>61</volume>:<fpage>523</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-005-0955-0</pub-id><pub-id pub-id-type="pmid">16007420</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
